Special Report: Western Australia- and Switzerland-based Creso Pharma (ASX:CPH) has secured a key advisor – the man who founded the biggest cannabis company in the world.

Bruce Linton, the founder and former chief executive of Canopy Growth Corporation, will join Creso as a strategic advisor, where he will leverage his connections, expertise and influence in the industry to consult and work closely with Creso Pharma’s board to shape its long-term strategy.

Linton says he was attracted to Creso Pharma for its unique intellectual property, global distribution footprint and robust product pipeline targeting distinct categories.

As previously reported, Creso was the first company to import medical cannabis into Australia, has won orders from distributors in Canada, Israel and South Africa and has imported animal health product anibidiol to its multinational partner Virbac.


Canopy’s amazing success story

Still, that is dwarfed by the success enjoyed by Canopy Growth, which Linton led through 16 rounds of financing of over $US5bn ($7bn) and over 30 mergers and acquisitions worth a total of $US3bn.

Under Linton’s leadership, Canopy became the first cannabis company to list on the New York Stock Exchange, in May 2018, where it remains the world’s biggest cannabis company by market valuation.

Linton left Canopy Growth in 2019, and currently sits as executive chairman of Gage Cannabis Co and director of psychedelic medicine company Mind Medicine.

He’s also the co-chairman and former chief executive of technology company Martello Technologies Group, and a co-founder of Ruckify Software, as well as having worked extensively with international institutions such as The World Bank.

“Bruce brings a wealth of invaluable knowledge and a deep network of cannabis industry contacts to Creso Pharma and we anticipate that his appointment will greatly assist us in achieving our near-term operation milestones and longer-term goals,” Creso chief executive Miri Halperin Wernli said.

“We continue to target international distribution agreements in a number of new markets and progress product development initiatives that will unlock considerable shareholder value.”

This article was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.